Publications by authors named "Maria Roche"

Claim this Profile
C
Chronic Anaphylaxis With Indolent Systemic Mastocytosis: A Case Report.
Sarah Worth, Tracy I George, Daniel J Shaheen, Maria Roche, Pankit Vachhani

Case Rep Hematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avapritinib versus Placebo in Indolent Systemic Mastocytosis.
Jason Gotlib, Mariana Castells, Hanneke Oude Elberink, Frank Siebenhaar, Karin Hartmann, Maria Roche

NEJM Evid· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.
Yoon-Koo Kang, Suzanne George, Robin L Jones, Piotr Rutkowski, Lin Shen, Maria Roche

J Clin Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors.
Cissimol P Joseph, Sarah N Abaricia, Michelle A Angelis, Kathleen Polson, Robin L Jones, Maria Roche

Oncologist· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy.
Suzanne George, Robin L Jones, Sebastian Bauer, Yoon-Koo Kang, Patrick Schöffski, Maria Roche

Oncologist· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial.
Robin L Jones, César Serrano, Margaret von Mehren, Suzanne George, Michael C Heinrich, Maria Roche

Eur J Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.
Michael C Heinrich, Robin L Jones, Margaret von Mehren, Patrick Schöffski, César Serrano, Maria Roche

Lancet Oncol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: and Preclinical Models.
Elayne Chan-Penebre, Kelli Armstrong, Allison Drew, Alexandra R Grassian, Igor Feldman, Maria Roche

Mol Cancer Ther· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism.
Alexandra Zanin-Zhorov, Jonathan M Weiss, Melanie S Nyuydzefe, Wei Chen, Jose U Scher, Maria Roche

Proc Natl Acad Sci U S A· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative estimation of the impact of caprine arthritis encephalitis virus infection on milk production by dairy goats.
Bernardo Martínez-Navalón, Cristòfol Peris, Ernesto A Gómez, Bernat Peris, María Luz Roche

Vet J· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma.
Susana M Campos, Richard T Penson, Ursula Matulonis, Neil S Horowitz, Christin Whalen, Maria Roche

Gynecol Oncol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In-band optical signal-to-noise ratio monitoring method based on high-resolution polarization analysis and induced differential group delay.
Juan José Martínez, Asier Villafranca, Carlos D Heras, Maria I Roche, Jesús M Subias

Appl Opt· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Albuminuria as a marker of kidney and cardio-cerebral vascular damage. Isle of Youth Study (ISYS), Cuba.
Raúl Herrera, Miguel Almaguer, José Chipi, Orquídia Martínez, Jorge Bacallao, María del Carmen Roche

MEDICC Rev· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors.
Maria R Roche, Pandora J Rudd, Carolyn N Krasner, Ursula A Matulonis, Suzanne T Berlin

Gynecol Oncol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.
Richard T Penson, Don S Dizon, Stephen A Cannistra, Maria R Roche, Carolyn N Krasner

J Clin Oncol· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
Ursula A Matulonis, Suzanne Berlin, Percy Ivy, Karin Tyburski, Carolyn Krasner, Maria Roche

J Clin Oncol· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
Ursula A Matulonis, Neil S Horowitz, Susana M Campos, Hang Lee, Julie Lee, Maria R Roche

J Clin Oncol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Screening for domestic violence in an oncology clinic: barriers and potential solutions.
Ashli Owen-Smith, Jeanne Hathaway, Maria Roche, Marie Elena Gioiella, Denise Whall-Strojwas

Oncol Nurs Forum· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Demographic, risk factor, and knowledge differences between Latinas and non-Latinas referred to colposcopy.
Marcela G del Carmen, Molly Findley, Alona Muzikansky, Maria Roche, Cori L Verrill

Gynecol Oncol· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug evaluation: tesetaxel--an oral semisynthetic taxane derivative.
Maria Roche, Helena Kyriakou, Michael Seiden

Curr Opin Investig Drugs· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case records of the Massachusetts General Hospital. Case 11-2006. A 54-year-old woman with a mass in the pelvis.
Carolyn N Krasner, Maria Roche, Neil S Horowitz, Jeffrey G Supko, Susanna I Lee

N Engl J Med· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy.
Amber Klein, Xiaoying He, Maria Roche, Allison Mallett, Linda Duska

Gynecol Oncol· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer.
Ursula A Matulonis, Michael V Seiden, Maria Roche, Carolyn Krasner, Arlan F Fuller

J Pain Symptom Manage· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.
Anna Berkenblit, Michael V Seiden, Ursula A Matulonis, Richard T Penson, Carolyn N Krasner, Maria Roche

Gynecol Oncol· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer.
Michael V Seiden, Franco Muggia, Allan Astrow, Ursula Matulonis, Susanna Campos, Maria Roche

Gynecol Oncol· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis